Advertisement

Curcumin prevented human autocrine growth hormone (GH) signaling mediated NF-κB activation and miR-183-96-182 cluster stimulated epithelial mesenchymal transition in T47D breast cancer cells

  • Ajda Coker-Gurkan
  • Derya Bulut
  • Recep Genc
  • Elif-Damla Arisan
  • Pınar Obakan-Yerlikaya
  • Narcin Palavan-Unsal
Original Article
  • 68 Downloads

Abstract

Autocrine growth hormone (GH) signaling is a promoting factor for breast cancer via triggering abnormal cell growth, proliferation, and metastasis, drug resistance. Curcumin (diferuloylmethane), a polyphenol derived from turmeric (Curcuma longa), has anti-proliferative, anti-carcinogenic, anti-hormonal effect via acting on PI3K/Akt, NF-κB and JAK/STAT signaling. Forced GH expression induced epithelial mesenchymal transition (EMT) through stimulation of miR-182-96-183 cluster expression in breast cancer cells. This study aimed to investigate the role of NF-κB signaling and miR-182-96-183 cluster expression profile on autocrine GH-mediated curcumin resistance, which was prevented by time-dependent curcumin treatment in T47D breast cancer cells. Dose- and time-dependent effect of curcumin on T47D wt and GH+ breast cancer cells were evaluated by MTT cell viability and trypan blue assay. Apoptotic effect of curcumin was determined by PI and Annexin V/PI FACS flow analysis. Immunoblotting performed to investigate the effect of curcumin on PI3K/Akt/MAPK, NF-κB signaling. miR182-96-183 cluster expression profile was observed by qRT-PCR. Overexpression of GH triggered resistant profile against curcumin (20 µM) treatment for 24 h, but this resistance was accomplished following 48 h curcumin exposure. Concomitantly, forced GH induced invasion and metastasis through EMT and NF-κB activation were prevented by long-term curcumin exposure in T47D cells. Moreover, 48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells. In consequence, curcumin treatment for 48 h, prevented autocrine GH-triggered invasion-metastasis, EMT activation through inhibiting NF-κB signaling and miR-182-96-183 cluster expression and induced apoptotic cell death by modulating Bcl-2 family members in T47D breast cancer cells.

Keywords

Breast cancer NF-κB Epithelial mesenchymal transition miRNA 

Abbreviations

BRMS1L

Breast cancer metastasis suppressor-1 like

DAPI

4′,6-Diamidino-2-phenylindole

DiOC6

3,3′-Dihexyloxacarbocyanine iodide

DMSO

Dimethylsulfoxide

EMT

Epithelial to mesenchymal transition

GH

Growth hormone

GHR

GH receptor

miRNAs

microRNAs

MMP

Matrix metalloproteinase

NF-κB

Nuclear factor kappa B

PI

Propidium iodide

PVDF

Polyvildifluoride

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

STAT-5

Signal transducer and activator of transcription 5

TBS

Tris-buffered saline

TIMP

Tissue inhibitory matrix proteinase

VEGF

Vascular endothelial growth factor

Notes

Acknowledgements

This work was supported by The Scientific and Technological Research Council of TURKEY (TUBITAK), Grand Number: 113Z791 and Istanbul Kultur University Scientific Projects Support Center. Authors wish to thank Busra Alper for her technical support in some immunoblotting results in Figs. 1d, 3a, 4a, 5a.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not involve any studies with human participants or animals performed by any of the authors. The research has been performed on commercially available cell lines.

Supplementary material

11033_2018_4479_MOESM1_ESM.jpg (64 kb)
The growth hormone expression profile in T47D GH+ breast cancer cell. The time dependent extracellular expression of GH in T47D breast cancer cell after GH inserted pcDNA3.1 (+) vector transfection and neomycin selection was determined by A. Immunoblotting and B. GH ELISA. P: Pellet, M: Medium, Humotrop was used as a positive control and β-actin was selected as a loading control.

References

  1. 1.
    Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE, Perry JK (2009) Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150:1341–1352CrossRefGoogle Scholar
  2. 2.
    Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE (2004) Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101:15166–15171CrossRefGoogle Scholar
  3. 3.
    Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE (2005) Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65:317–324PubMedGoogle Scholar
  4. 4.
    Chen YJ, Zhang X, Wu ZS, Wang JJ, Lau AY, Zhu T, Lobie PE (2015) Autocrine human growth hormone stimulates the tumor initiating capacity and metastasis of estrogen receptor-negative mammary carcinoma cells. Cancer Lett 365:182–189CrossRefGoogle Scholar
  5. 5.
    Mojarrad M, Momeny M, Mansuri F, Abdolazimi Y, Tabrizi MH, Ghaffari SH, Tavangar SM, Modarressi MH (2010) Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med Oncol 27:474–480CrossRefGoogle Scholar
  6. 6.
    Bougen NM, Yang T, Chen H, Lobie PE, Perry JK (2011) Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. Oncol Rep 26:487–493PubMedGoogle Scholar
  7. 7.
    Minoia M, Gentilin E, Mole D, Rossi M, Filieri C, Tagliati F, Baroni A, Ambrosio MR, E degli Uberti, Zatelli MC (2012) Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. J Clin Endocrinol Metab 97:E907–E916CrossRefGoogle Scholar
  8. 8.
    Chauhan DP (2002) Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 8:1695–1706CrossRefGoogle Scholar
  9. 9.
    Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, Nerlich AG, Bachmeier BE (2012) Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and – 2. Carcinogenesis 33:2507–2519CrossRefGoogle Scholar
  10. 10.
    Odot J, Albert P, Carlier A, Tarpin M, Devy J, Madoulet C (2004) In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111:381–387CrossRefGoogle Scholar
  11. 11.
    Kim B, Kim HS, Jung EJ, Lee JY, B KT, Lim JM, Song YS (2016) Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Mol Carcinog 55:918–928CrossRefGoogle Scholar
  12. 12.
    Zhu Y, Bu S (2017) Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells. Evid Complement Alternat Med 2017:5787218Google Scholar
  13. 13.
    Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB, Kong B (2014) Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol 7:2818–2824PubMedPubMedCentralGoogle Scholar
  14. 14.
    Thangapazham RL, Sharma A, Maheshwari RK (2006) Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 8:E443–E449CrossRefGoogle Scholar
  15. 15.
    Pires BR, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Diaz JA, Maia AM, Correa S, Abdelhay ES (2017) NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE 12:e0169622CrossRefGoogle Scholar
  16. 16.
    Garg M (2013) Epithelial-mesenchymal transition—activating transcription factors—multifunctional regulators in cancer. World J Stem Cells 5:188–195CrossRefGoogle Scholar
  17. 17.
    Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG (2010) microRNA, cell cycle, and human breast cancer. Am J Pathol 176:1058–1064CrossRefGoogle Scholar
  18. 18.
    Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866CrossRefGoogle Scholar
  19. 19.
    Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z, Zhu Q (2014) MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res 16:473CrossRefGoogle Scholar
  20. 20.
    Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM, Sun Y, Chen XF (2016) Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget 7:42805–42825PubMedPubMedCentralGoogle Scholar
  21. 21.
    Coker-Gurkan A, Celik M, Ugur M, Arisan ED, Obakan-Yerlikaya P, Durdu ZB, Palavan-Unsal N (2018) Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-kappaB signaling and polyamine metabolism in breast cancer cells. Amino AcidsGoogle Scholar
  22. 22.
    Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148:779–790CrossRefGoogle Scholar
  23. 23.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefGoogle Scholar
  24. 24.
    Negri E, Braga C, La Vecchia C, Franceschi S, Parazzini F (1997) Family history of cancer and risk of breast cancer. Int J Cancer 72:735–738CrossRefGoogle Scholar
  25. 25.
    Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012:654–698CrossRefGoogle Scholar
  26. 26.
    Siriwardana G, Bradford A, Coy D, Zeitler P (2006) Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20:2010–2019CrossRefGoogle Scholar
  27. 27.
    Bahadori F, Demiray M (2017) A realistic view on “the essential medicinal chemistry of curcumin”. ACS Med Chem Lett 8:893–896CrossRefGoogle Scholar
  28. 28.
    Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA (2017) The essential medicinal chemistry of curcumin. J Med Chem 60:1620–1637CrossRefGoogle Scholar
  29. 29.
    Lanning NJ, Carter-Su C (2006) Recent advances in growth hormone signaling. Rev Endocr Metab Disord 7:225–235CrossRefGoogle Scholar
  30. 30.
    Waters MJ, Conway-Campbell BL (2004) The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci USA 101:14992–14993CrossRefGoogle Scholar
  31. 31.
    Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G (2007) Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73:1024–1032CrossRefGoogle Scholar
  32. 32.
    Thacker PC, Karunagaran D (2015) Curcumin and emodin down-regulate TGF-beta signaling pathway in human cervical cancer cells. PLoS ONE 10:e0120045CrossRefGoogle Scholar
  33. 33.
    Gallardo M, Calaf GM (2016) Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines. Int J Oncol 49:1019–1027CrossRefGoogle Scholar
  34. 34.
    Zhang W, Qian P, Zhang X, Zhang M, Wang H, Wu M, Kong X, Tan S, Ding K, Perry JK, Wu Z, Cao Y, Lobie PE, Zhu T (2015) Autocrine/paracrine human growth hormone-stimulated microRNA 96-182-183 cluster promotes epithelial-mesenchymal transition and invasion in breast cancer. J Biol Chem 290:13812–13829CrossRefGoogle Scholar
  35. 35.
    Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569–581CrossRefGoogle Scholar
  36. 36.
    Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310CrossRefGoogle Scholar
  37. 37.
    Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293:1495–1499CrossRefGoogle Scholar
  38. 38.
    Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 3:120CrossRefGoogle Scholar
  39. 39.
    Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, Thorgeirsson SS (2015) Curcumin effectively inhibits oncogenic NF-kappaB signaling and restrains stemness features in liver cancer. J Hepatol 63:661–669CrossRefGoogle Scholar
  40. 40.
    Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A, Alajez NM (2017) Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis 8:e3045CrossRefGoogle Scholar
  41. 41.
    Wang W, Luo YP (2015) MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B 16:18–31CrossRefGoogle Scholar
  42. 42.
    Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y, Cai Z (2012) Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS ONE 7:e52280CrossRefGoogle Scholar
  43. 43.
    Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Puijenbroek A, van Noort PI, Prevost GP, Schaapveld RQ, Cuppen E (2012) A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS ONE 7:e43569CrossRefGoogle Scholar
  44. 44.
    Qiu M, Liu L, Chen L, Tan G, Liang Z, Wang K, Liu J, Chen H (2014) microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. Biochem Biophys Res Commun 452:163–169CrossRefGoogle Scholar
  45. 45.
    Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J (2012) TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 122:3563–3578CrossRefGoogle Scholar
  46. 46.
    Zekri A, Ghaffari SH, Yousefi M, Ghanizadeh-Vesali S, Mojarrad M, Alimoghaddam K, Ghavamzadeh A (2013) Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis. Mol Cell Endocrinol 377:84–92CrossRefGoogle Scholar
  47. 47.
    Bougen NM, Steiner M, Pertziger M, Banerjee A, Brunet-Dunand SE, Zhu T, Lobie PE, Perry JK (2012) Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. Endocr Relat Cancer 19:625–644CrossRefGoogle Scholar
  48. 48.
    Zhu Z, Mukhina S, Zhu T, Mertani HC, Lee KO, Lobie PE (2005) p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 24:3774–3785CrossRefGoogle Scholar
  49. 49.
    Berrak O, Akkoc Y, Arisan ED, Coker-Gurkan A, Obakan-Yerlikaya P, Palavan-Unsal N (2016) The inhibition of PI3K and NFkappaB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. Biomed Pharmacother 77:150–160CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Molecular Biology and Genetics Department, Science and Letters FacultyIstanbul Kultur UniversityIstanbulTurkey

Personalised recommendations